Our Global Leadership Team

Our executive team is drawn from the leadership of Stallergenes and Greer together with external biopharmaceutical talent. Together they form a forward-thinking and collaborative multi-cultural group dedicated to leading our employees and partners toward our vision of worldwide freedom from allergy.

Chairman and CEO Stallergenes Greer

Fereydoun Firouz

Mr. Firouz has 27 years pharmaceutical industry experience and was President and CEO of EMD Serono, Inc. and Head of the Global Business Unit Fertility and Endocrinology franchise. He was also a member of the Executive Management Board of Merck Serono.

From 2001 to 2003, Mr. Firouz was Executive Vice President, Reproductive Health North America, and from 1998 to 2001, he was Vice President, Latin America for Serono S.A.

He is a past Board Member of the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO), and the Massachusetts Biotech Council (MBC).

Mr. Firouz received a Bachelor of Arts in Political Science from George Washington University. He has participated in executive MBA programs at the Kellogg Business School and Babson College.

Executive Vice President, Head of Europe & International, President of Stallergenes SAS

Michele Antonelli

Michele Antonelli has more than 20 years of international experience in the biopharmaceutical industry with extensive expertise in both manufacturing and commercial.

He joined Stallergenes SAS in November 2015 as Executive Vice President, Head of International Operations. Michele previously worked at UCB where he held roles of various responsibility and scope, most recently serving as Executive Vice President and Head of lmmunology Europe, overseeing the region’s commercial, medical, and market access activities. Prior to joining UCB, Michele spent 16 years at Merck Serono, ultimately serving as Senior Vice President and Global Head of Biotech Manufacturing and Process Development.

Executive Vice President, Head Of Americas, President & CEO Stallergenes Greer Inc.

Richard (Rick) Russell

Richard (Rick) Russell will lead the Americas for Stallergenes Greer.  He has more than 20 years of experience leading commercial operations and in developing and implementing sales and marketing activities for major pharmaceutical brands in North America and the European Union.

His pharmaceutical experience spans many therapeutic areas ranging from central nervous system (CNS) disorders, women’s health, cardiovascular disease and neurodegenerative disorders.  Most recently, Rick was Chief Commercial Officer at Sunovion, where he led commercial operations for a portfolio of eight products generating $1.5 billion in revenue.  Previously, he was the U.S. Executive Vice President, Neurodegenerative Diseases and Rheumatology at EMD Serono, where he managed all sales and marketing activities for the multiple sclerosis franchise.  Earlier in his career, Rick was Vice President, Marketing at Sanofi-Aventis, and has held several roles in sales and marketing leadership.  He is a graduate of Bates College and the University of New Hampshire

General Counsel and Company Secretary

Devin Smith

Devin Smith joined the company from EMD Serono, Inc., the biopharmaceutical division of Merck KGaA, Darmstadt, Germany.  At EMD Serono, Devin Smith lead the North American legal department as Vice President and General Counsel.

Prior to EMD Serono, Devin Smith was an associate lawyer and then partner at the international law firm of Nixon Peabody LLP, where he represented emerging and established life science, information technology and manufacturing businesses. 

Devin Smith received his law degree (cum laude) from Suffolk University Law School and a B.A. in political science from the University of North Carolina - Chapel Hill.